BTK and epilepsy: In summary, given the known mechanisms of action of BTK inhibitors, anti-CD 20 monoclonal antibody, and teriflunomide, our findings hint at the possibility of considering these medications for potential repurposing opportunities for the treatment of epilepsy and provide plausibility for a potential pathogenic role of leukocyte subsets in the perpetuation of epileptic seizures.